Anti-metastatic activity in vivo of MDP-L-alanyl-cholesterol (MTP-Chol) entrapped in nanocapsules.
A lipophilic muramylpeptide (MTP-Chol), capable of rendering macrophages cytostatic towards tumour cells, was encapsulated within polyisobutylcyanoacrylate nanocapsules and administered to mice carrying an experimental model of liver metastasis. Treatment by intravenous injections twice a week beginning before the establishment of metastases significantly reduced the number of liver colonies. Treatment started later was less effective. The dose of MTP-Chol in each injection, and the tumour burden in the mice did not change the percentage inhibition of metastases significantly. Anti-metastatic activity was also observed after administering nanocapsules containing MTP-Chol by the oral route.
Yu
W P
WP
CNRS URA 1218, Centre d'Etudes Pharmaceutiques, Chatenay-Malabry, France.
Barratt
G M
GM
Devissaguet
J P
JP
Puisieux
F
F
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002214:Capsules; D002788:Cholesterol Esters / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D005260:Female; D008262:Macrophage Activation / Q000187:drug effects; D051379:Mice; D008810:Mice, Inbred C57BL; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000276:immunology / Q000556:secondary
D000970:Antineoplastic Agents; D002214:Capsules; D002788:Cholesterol Esters; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C047489:N-acetylmuramyl-alanyl-isoglutamine-alanyl-cholesterol